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A member of the family of L-riboside benzimidazole compounds, 1263W94, was shown recently to inhibit
replication of Epstein-Barr virus (EBV) (V. L. Zacny, E. Gershburg, M. G. Davis, K. K. Biron, and J. S. Pagano,
J. Virol. 73:7271–7277, 1999). In the present report the effect of 1263W94 on the phosphorylation pattern of
the EBV DNA polymerase processivity factor, EA-D, during viral reactivation in latently EBV-infected Akata
cells is analyzed. This pattern specifically changes with progression of cytolytic infection. In the presence of
1263W94 the appearance of the hyperphosphorylated form of EA-D is mainly affected. Next, coexpression of the
cloned EBV-encoded protein kinase (EBV PK), BGLF4, with EA-D demonstrated the ability of EBV PK to
phosphorylate EA-D to its hyperphosphorylated form in transient assays. However, the phosphorylation of
EA-D was not directly inhibited by 1263W94 in these coexpression assays. The results indicate that the EBV
PK appears to be responsible for the hyperphosphorylation of EA-D, imply that the phosphorylation status of
EA-D is important for viral replication, and suggest that 1263W94 acts at a level other than direct inhibition
of EA-D phosphorylation by EBV PK.
Epstein-Barr virus (EBV) is a human gammaherpesvirus
that causes infectious mononucleosis and is closely associated
with several types of human malignancy, including B-cell lym-
phomas (19), some T-cell lymphomas (24), nasopharyngeal
carcinoma, and Hodgkin’s disease (2, 11, 31). Despite the
availability of antiviral drugs (reviewed in references 28 and
32) treatment for EBV infections remains undeveloped.
1263W94 [5,6-dichloro-2-(isopropylamino)-1--L-ribofurano-
syl-1H-benzimidazole] (21), a member of the benzimidazole
ribonucleoside family (10), was shown to possess both anti-
human cytomegalovirus (HCMV) (21) and, later, anti-EBV
activity (42). The compound does not inhibit replication of
herpes simplex virus (HSV) and varicella-zoster virus (VZV)
(V. L. Zacny, M. G. Davis, S. D. Chamberlain, L. B. Townsend,
K. K. Biron, and J. S. Pagano, Abstr. 37th Intersci. Conf.
Antimicrob. Agents Chemother., abstr. H69, 1997). It inhibits
HCMV replication by a novel mechanism: although viral DNA
synthesis is inhibited, the HCMV DNA polymerase is not a
target (reviewed in reference 8). Recently, we have shown that
the compound affects the phosphorylation pattern of the EBV
DNA polymerase processivity factor (EA-D) (42). EA-D plays
an important role in viral replication as an essential component
of the EBV DNA polymerase complex (13, 14, 37, 38). It also
interacts with the viral transactivator BZLF1 (43) and cellular
transcription factors Sp1 and ZBP-89 at the origin of lytic
replication (oriLyt) (3). It was shown years ago that EA-D is
phosphorylated to different levels during viral reactivation (12,
33); however, the importance of the EA-D phosphorylation for
viral replication remains unclear.
Resistance to 1263W94 in HCMV was mapped to the UL97
gene (C. L. Talarico, M. G. Davis, P. B. Sethna, W. H. Miller,
M. R. Underwood, F. Baldanti, K. K. Biron, and R. J. Harvey,
38th Intersci. Conf. Antimicrob. Agents Chemother., abstr.
140-H, 1998), the product of which is a phosphotransferase
(16, 34, 36). Homologs of this protein are encoded by all
known herpesviruses; they contain conserved cyclic AMP-de-
pendent protein kinase key catalytic residues (23). Protein
kinase activity has already been demonstrated for HSV-1
UL13 (30), VZV ORF47 (25), and HCMV UL97 (16) and
recently for EBV BGLF4 (7, 18).
In this report we show that EA-D is a substrate for the EBV
protein kinase (EBV PK), BGLF4. Despite the fact that the
phosphorylation pattern of EA-D during viral reactivation is
altered by 1263W94, the compound failed to inhibit phosphor-
ylation of EA-D when the isolated gene products were over-
expressed.
MATERIALS AND METHODS
Cell lines. Akata is a Burkitt’s lymphoma cell line latently infected with EBV
(35), DG75 is an EBV-negative Burkitt’s lymphoma cell line (4), and 293T is a
transformed human embryonal kidney cell line. The cells were grown as de-
scribed previously (42).
Treatment of cells with antiviral compounds and viral reactivation. 1263W94
and acyclovir (ACV) were supplied by GlaxoSmithKline. Exponentially growing
cells were centrifuged at 800  g and suspended in fresh medium containing
different concentrations of either compound for an appropriate time as indi-
cated. At the end of the treatment, cells were harvested and analyzed depending
on the aim of experiment.
To reactivate lytic viral infection Akata cells were treated with goat anti-
human immunoglobulin G (IgG) (0.1 mg/ml; Sigma). Treatment with antiviral
compounds and viral reactivation were begun at the same time.
Plasmids and transfections. The BGLF4 open reading frame (ORF)
(genomic position 122327 to 123691) and the BMRF1 ORF (genomic posi-
tion 79898 to 81112) from the BamHI-G fragment and pSG5-BMRF1, re-
spectively, were PCR amplified using primer pair 5-CCGGATCCCAGCGG
GTGGAGG/5-CCGGATCCCTCCACGTCGGCC for BGLF4 amplification
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and primer pair 5-CCGGATCCCATGGAAACCACTCAGAC/5-CCGGATC
CAGGTGCTGCTTGCACGAG for BMRF1 amplification. Amplified BMRF1
ORF was cloned downstream of the cytomegalovirus immediate-early promoter
in the pGEM2-based vector pHD101.3 (9) and the plasmid named pHD/
BMRF1. The BGLF4 ORF was cloned downstream of the same promoter in
pHD101.3, and the resulting plasmid was named pHD/BGLF4. The kinase-null
mutant of BGLF4 was generated by site-directed mutagenesis that replaced
lysine-128 with glutamine. The K128Q mutant was cloned into pHD101.3; the
resulting plasmid was designated pHD/K128Q. The orientation of inserts was
confirmed by restriction analysis and sequencing.
293T cells were transfected with 0.1 to 10 g of plasmid DNA with the use of
Effectine (QIAgen) following the manufacturer’s protocol. Transfected cells
were cultured in Dulbecco’s modified Eagle medium supplemented by 10% fetal
bovine serum and antibiotics for 24 to 48 h at 37°C and then harvested for
analysis.
RNA extraction and RPA. Total RNA was isolated from the cells with the use
of the RNeasy total RNA isolation kit (QIAgen). RNase protection assays
(RPA) were performed with 10 g of total RNA with the use of the RNase
Protection kit II (Ambion Inc.) following the manufacturer’s protocol. The
hybridization temperature was 45°C. Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) probe was supplied by U.S. Biochemical Inc. (probe size, 129 bp;
protected region, 100 bp). BGLF4 probe was generated with NdeI-digested
pHD/BGLF4 as a template and SP6 RNA polymerase (probe size, 185 bp;
protected region, 157 bp). BMRF1 transcription served as a positive control, and
the BMRF1 probe was generated with NotI-digested pHD/BMRF1 as a template
and SP6 RNA polymerase (probe size, 339 bp; protected region, 311 bp).
Protein lysates and immunoblotting. Cells were washed once with ice-cold
phosphate-buffered saline solution and then resuspended in lysis buffer (50 mM
Tris-HCl, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 5 mM dithiothreitol, 0.2
mM Na3VaO4, 100 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and a cock-
tail of protease inhibitors [Complete; Boehringer]). Protein concentration was
determined by the Bradford protein assay (Bio-Rad).
For immunoblotting, equal amounts of protein lysates were separated by
polyacrylamide gel electrophoresis on a sodium dodecyl sulfate polyacrylamide
gel (10%). Proteins were transferred to NitroPlus (MSI) nitrocellulose and
detected by appropriate antibody. For all Western analyses proteins were visu-
alized with anti-mouse Ig-horseradish peroxidase (Amersham), SuperSignal
(Pierce), and Kodak XAR-5 film.
Monoclonal antibodies to EA-D were purchased from Capricorn Products Inc.
and used at a dilution of 1:100; monoclonal antibodies to -actin and -tubulin
(Sigma) were used at a dilution of 1:5,000.
RESULTS
1263W94 inhibits the phosphorylation of EA-D during viral
reactivation. To determine the phosphorylation status of
EA-D during the viral cytolytic cycle, viral replication in la-
tently EBV-infected Akata cells was induced with anti-IgG in
the presence or absence of 10 M 1263W94, a concentration
10 times greater than the 50% inhibitory concentration (42).
Whole-cell lysates were prepared at different times after in-
duction and analyzed by immunoblotting.
No EA-D was detected in uninduced cells (Fig. 1, lane 1);
however, after induction two major phosphorylated forms of
EA-D appeared. The forms are named “pp50” and “pp58,”
where “pp” stands for “phosphoprotein” and the numbers re-
fer to molecular masses in kilodaltons (33). The hyperphos-
phorylated form pp58 appeared 8 h after induction when it was
the only form detected (lane 3). It reached its peak amount at
24 h and then declined 48 h after induction (lanes 5 and 6). The
hypophosphorylated form pp50 appeared later (lane 4); how-
ever, its level remained high until the end of the experiment
(lanes 5 and 6). From a comparison of these results with the
1263W94-treated samples it is clear that the compound re-
duced the overall amount of EA-D (Fig. 1, compare lanes 3
with 8, 4 with 9, 5 with 10, and 6 with 11, respectively). The
level of pp58 was especially affected (compare lanes 5 with 10
and 4 with 11); it was strongly inhibited by the compound by
24 h and no longer detected at 48 h after viral reactivation.
These data show that the phosphorylation pattern of EA-D
changes during the viral lytic cycle and imply that EA-D phos-
phorylation status might be important for its function. This
hypothesis is enhanced by the fact that the waning of pp58 in
the presence of 1263W94 accompanied the inhibition of viral
replication (42).
RNA level of EBV PK during viral reactivation and effect of
1263W94. We next began to characterize the BGLF4 gene
product, which encodes the EBV PK (7, 18), by examining the
time course of its mRNA. With the use of RPA we measured
BGLF4 mRNA accumulation during viral reactivation in
Akata cells in the presence of 1263W94 or ACV as a control.
The cells were induced and treated with either compound as
described above. Transcript levels of the EA-D-encoding gene,
FIG. 1. Effect of 1263W94 on EBV EA-D in induced Akata cells. Akata cells were induced as described in Materials and Methods for 48 h.
Cells were harvested at 4, 8, 12, 24, and 48 h, and equal amounts of the whole-cell lysates were analyzed by immunoblotting. Lanes 1 to 6, no
1263W94; lanes 7 to 11, samples treated with 10 M 1263W94; lane 1, noninduced (n.i.) control.
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BMRF1, served as an early gene control. mRNAs of both
genes appeared 4 h after induction (Fig. 2, lanes 2, 8 and 16);
both levels peaked between 8 and 12 h after induction (lanes 3
and 4, 9 and 10, and 17 and 18) and declined to barely detect-
able levels 48 h after induction (lanes 6, 12, and 20). Treatment
with either drug did not significantly affect BGLF4 or BMRF1
mRNA levels (compare lanes 7 to 12, 1 to 6, and 15 to 20),
which were measured by normalizing of BGLF4 and BMRF1
mRNA levels to the GAPDH RNA level using a Phosphor-
Imager. Neither BGLF4 nor BMRF1 mRNA was detected in
the EBV-negative control cells (DG75) (lane 13) or in unin-
duced Akata cells (lanes 1, 7, and 15).
These data demonstrate that BGLF4 is an early gene and its
expression is temporally associated with the phosphorylation
of EA-D (Fig. 1). 1263W94 and ACV did not affect BGLF4
mRNA levels, consistent with inhibition at translational or
posttranslational levels.
EBV PK hyperphosphorylates EA-D protein. To determine
if the viral protein kinase encoded by BGLF4 is indeed respon-
sible for EA-D phosphorylation, we cloned both BMRF1 and
BGLF4 ORFs under the control of a constitutive promoter
and cotransfected the plasmids into an EBV-negative cell line,
293T. With the use of whole-cell lysates prepared from the
transfected cells followed by immunoblotting, changes in
EA-D phosphorylation status were detected by a shift in mo-
lecular mass upon sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. To confirm that this shift was due to phos-
phorylation the lambda phosphatase assay was employed. Ex-
pression of EA-D alone resulted in the appearance of a single
band with a molecular mass of 50 kDa (pp50) that represents
a hypophosphorylated form of EA-D. This result suggests that
such a level of EA-D phosphorylation may be achieved by
cellular kinases (Fig. 3, lane 1). Coexpression with EBV PK
resulted in a complete shift to the hyperphosphorylated form
(pp58) (lane 3). This shift up in molecular mass was greatly
reduced when EA-D was coexpressed with the kinase-dead
mutant of BGLF4, K128Q (lane 5). Finally, lambda phospha-
tase treatment resulted in a shift down in the molecular mass
FIG. 2. Kinetics of EBV PK (BGLF4) RNA during viral reactivation and effect of 1263W94. Induced Akata cells were harvested at 0, 4, 8, 12,
24, and 48 h after induction. Total RNA (10 g) from each sample was analyzed by RPA. Lane 13 is a negative control (total RNA prepared from
DG 75 cells); lanes 1, 7, and 15, noninduced Akata cells; lanes 8 to 12, Akata cells induced with IgG; lanes 2 to 6, Akata cells treated with 1263W94
and induced with IgG; lanes 16 to 20, Akata cells treated with ACV and induced with IgG. Yeast RNA (lane 14) was used as a negative control.
Positions only of undigested probes are indicated by arrows.
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of the EA-D band to the nonphosphorylated level (46 to 48
kDa) (lanes 2, 4, and 6). The lysate from induced Akata cells
was used as a molecular weight control (lane 7). No EA-D
protein was detected in transfections with the vector (not
shown).
These results suggest that EA-D protein may be phosphor-
ylated to some extent by cellular kinases, but it is hyperphos-
phorylated specifically by the viral protein kinase BGLF4.
1263W94 fails to inhibit hyperphosphorylation of EA-D by
EBV PK. The pp58 form of EA-D is affected by 1263W94
during viral reactivation (Fig. 1). Since many EBV proteins are
expressed during viral reactivation, we coexpressed EA-D and
BGLF4 alone in 293T cells in order to determine if the hyper-
phosphorylation of EA-D by BGLF4 is impaired by 1263W94.
We transfected cells with decreasing amounts of BGLF4 and a
constant amount of BMRF1 (0.5 g). The results show that
1263W94 did not affect the appearance of pp58 (Fig. 4) and
imply that the inhibition of BGLF4 kinase activity, as reflected
by hyperphosphorylation of EA-D, is not directly affected by
the compound.
DISCUSSION
1263W94, a member of the L-riboside benzimidazole family,
possesses potent anti-EBV activity as shown previously (42).
EA-D is a major phosphoprotein produced during the early
phase of lytic infection (33) and an essential factor in an in
vitro replication system that uses EBV oriLyt (13). In an ex-
FIG. 3. Phosphorylation of EA-D by EBV PK in transient coexpression. 293T cells were either transfected with pHD/BMRF1 alone (lane 1)
or cotransfected with pHD/BGLF4 (lane 3) or pHD/K128Q (lane 5). Lanes 2, 4, and 6 contain the same extracts treated with lambda phosphatase
(-PPase). Akata cell protein extract (lanes 7 and 8) has been used as a size control. Cells were harvested 48 h after transfection, and equal amounts
of the protein lysates were analyzed by immunoblotting. The differences in amount of EA-D in lanes 1 and 2 are due to unequal loading.
FIG. 4. 1263W94 does not inhibit the phosphorylation of EA-D by EBV PK in coexpression assays. 293T cells were transfected as described
in the legend to Fig. 3. Equal amounts (0.5 g) of EA-D expression plasmid and serial dilutions of EBV PK expression plasmid (from 0.5 to 0.0625
g) were used. Cells were harvested 48 h after transfection, and equal amounts of protein lysates were analyzed by immunoblotting. Lanes 7 to
11 contain cells treated with 1263W94.
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tension of the earlier observations (42), we have shown that
EA-D hyperphosphorylation is detected by 8 h and is tempo-
rally regulated; the hyperphosphorylated form (pp58) appears
and wanes earlier than the hypophosphorylated form (pp50).
Moreover, the predominant effect of 1263W94 appears to be
on pp58, although the overall levels of both forms of EA-D are
also affected (Fig. 1). The pp58 form of EA-D has previously
been shown to contain both phosphoserine and phosphothreo-
nine, but pp50 contains phosphoserine only (33), which sup-
ports the hypothesis that EA-D is hyperphosphorylated by a
newly induced protein kinase. These observations imply that
the phosphorylation status of EA-D is probably important for
its functions. The results suggest that EA-D is probably phos-
phorylated by an induced protein kinase, presumably viral, and
that 1263W94 inhibits EBV replication at least partially
through its effect on hyperphosphorylated EA-D.
Beta- and gammaherpesviruses (including EBV) encode
only one protein kinase (23) that is homologous to HSV UL13.
UL13 has been shown to mediate the phosphorylation of viral
proteins (such as ICP22 [30], gE and gI [26], and ICP0 [27])
and cellular factors (such as translation elongation factor 1
delta [20] and p60 [6]), thereby affecting viral replication and
pathogenesis. EBV-encoded protein kinase BGLF4 has been
recently shown to phosphorylate the translation elongation
factor 1 delta (18) and appears to phosphorylate EA-D in vitro
(7). We first examined a time course of BGLF4 mRNA ex-
pression. Since BGLF4 mRNA appeared 6 h after reactivation
and was not affected by ACV treatment we concluded that
BGLF4 is an early gene. Its RNA kinetics are temporally
associated with the phosphorylation of EA-D (Fig. 1 and 2).
Taken together, our results and the previous report show that
BGLF4 is involved in EA-D hyperphosphorylation. 1263W94
did not affect significantly the mRNA level and presumably the
protein level of BGLF4.
EA-D contains several potential sites for phosphorylation by
protein kinase C and CKII cellular kinases. Indeed, our results
demonstrate that transient expression of EA-D in EBV-nega-
tive cells results in hypophosphorylation of the protein, chiefly
to the pp50 form (reference 42 and Fig. 3). However, coex-
pression of EA-D along with the BGLF4 gene product pro-
duces a complete shift from the pp50 to the pp58 form of
EA-D, which confirms that BGLF4 indeed possesses protein
kinase activity and that EA-D is one of its substrates.
These results and previous observations suggest a new mech-
anism of action for antiviral compounds active against herpes-
viruses. Essentially most drugs studied thus far act mainly on
herpesvirus DNA polymerase and cause DNA chain termina-
tion. The -D-riboside benzimidazole BDCRB, which inhibits
HCMV but not EBV replication (42), is thought to inhibit the
HCMV UL89 and UL56 (22, 39) gene products, as well as
virus maturation (41).
Although in our system 1263W94 did not directly inhibit the
hyperphosphorylation of EA-D by EBV PK (Fig. 4), it did
affect the pp58 level during viral reactivation in Akata cells,
suggesting that 1263W94 might act at other levels before or
after the phosphorylation. Our preliminary results indicate
that it might alter EA-D localization in the cell (not shown).
Interestingly, although other herpesviruses have homologous
DNA processivity factors (1, 5, 15, 40), HCMV and EBV are
the only viruses that are reported to be sensitive to 1263W94 so
far. It will be important to determine the phosphorylation
status and the functionality or localization of the DNA pro-
cessivity factors in herpesviruses both sensitive and insensitive
to the compound. This information would be valuable for de-
sign of antiviral agents targeting these proteins and formation
of the DNA polymerase complex.
Our results raise an important question. It has been reported
that a 1263W94-resistant mutant of HCMV has a point muta-
tion in the UL97 gene (Talarico et al., 38th ICAAC), which is
homologous to EBV BGLF4. Moreover, we show the effect of
the compound in altering the phosphorylation pattern of EA-D
during viral reactivation in Akata cells (Fig. 1), which led us to
the hypothesis that BGLF4 is involved in this process. Further-
more, a BGLF4 mutant bearing a mutation corresponding to
that in UL97 (L397R) failed to hyperphosphorylate EA-D in a
coexpression assay (not shown). However, 1263W94 did not
directly affect EA-D hyperphosphorylation by BGLF4 when
the two gene products were overexpressed in tandem. One
possible explanation is that despite the homology, these ki-
nases still have different targets; for example, the HSV-1 UL13
kinase induces directly or indirectly the phosphorylation of
HSV-1 ICP22 and does not affect the phosphorylation of ICP4
(29), while VZV ORF47 (the homolog of UL13) phosphory-
lates VZV ORF62 (the homolog of HSV-1 ICP4) but not
ORF63 (the homolog of HSV-1 ICP22) (17). Another possible
explanation is that the compound affects another EBV pro-
tein(s) that in turn regulates BGLF4. Thus, to better charac-
terize the role of BGLF4 in the EBV life cycle we are now
attempting to identify its targets and regulators using purified
protein and a number of antiviral compounds including
1263W94.
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